Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Interventional Post Approval Trial to Assess the Safety of Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (DME) in Patients in India.

NCT05511038 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05511038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05511038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Interventional Post Approval Trial to Assess the Safety of Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema (DME) in Patients in India.
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Completed
Start date
August 26, 2022
Completion date
April 16, 2024
Enrollment
100 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema